AIMS: Our goal was to evaluate the association between antidepressant use and the risk of coronary heart disease (CHD) among subjects with no history of coronary heart disease. METHODS: A search of Medline, EMBASE, PsycINFO and the Cochrane Library was performed in January 2013. Two authors independently reviewed and selected eligible observational studies, based on predetermined selection criteria. Pooled relative risks (RRs) with confidence intervals (CIs) were calculated using random-effects or fixed-effects models. RESULTS: Sixteen observational studies (seven case-control studies and nine cohort studies) were included in the final analysis. There was no association between selective serotonin reuptake inhibitor use and the risk of CHD overall [odds ratio (OR), 0.93; 95% CI, 0.65-1.33] or in subgroup meta-analysis of case-control studies (OR, 0.91; 95% CI, 0.60-1.37) and cohort studies (RR, 0.96; 95% CI, 0.59-1.55). The use of tricyclic antidepressant was associated with an increased risk of CHD overall (OR, 1.51; 95% CI, 1.07-2.12), but it was observed only in case-control studies (OR, 1.56; 95% CI, 1.24-1.96) and low-quality studies (OR, 1.49; 95% CI, 1.20-1.85) in the subgroup meta-analyses. CONCLUSIONS: This meta-analysis of observational studies in subjects with no history of CHD suggests that neither selective serotonin reuptake inhibitor nor tricyclic antidepressant use is associated with an increased risk of CHD.
AIMS: Our goal was to evaluate the association between antidepressant use and the risk of coronary heart disease (CHD) among subjects with no history of coronary heart disease. METHODS: A search of Medline, EMBASE, PsycINFO and the Cochrane Library was performed in January 2013. Two authors independently reviewed and selected eligible observational studies, based on predetermined selection criteria. Pooled relative risks (RRs) with confidence intervals (CIs) were calculated using random-effects or fixed-effects models. RESULTS: Sixteen observational studies (seven case-control studies and nine cohort studies) were included in the final analysis. There was no association between selective serotonin reuptake inhibitor use and the risk of CHD overall [odds ratio (OR), 0.93; 95% CI, 0.65-1.33] or in subgroup meta-analysis of case-control studies (OR, 0.91; 95% CI, 0.60-1.37) and cohort studies (RR, 0.96; 95% CI, 0.59-1.55). The use of tricyclic antidepressant was associated with an increased risk of CHD overall (OR, 1.51; 95% CI, 1.07-2.12), but it was observed only in case-control studies (OR, 1.56; 95% CI, 1.24-1.96) and low-quality studies (OR, 1.49; 95% CI, 1.20-1.85) in the subgroup meta-analyses. CONCLUSIONS: This meta-analysis of observational studies in subjects with no history of CHD suggests that neither selective serotonin reuptake inhibitor nor tricyclic antidepressant use is associated with an increased risk of CHD.
Authors: An Pan; Olivia I Okereke; Qi Sun; Giancarlo Logroscino; JoAnn E Manson; Walter C Willett; Alberto Ascherio; Frank B Hu; Kathryn M Rexrode Journal: Stroke Date: 2011-08-11 Impact factor: 7.914
Authors: François Lespérance; Nancy Frasure-Smith; Diana Koszycki; Marc-André Laliberté; Louis T van Zyl; Brian Baker; John Robert Swenson; Kayhan Ghatavi; Beth L Abramson; Paul Dorian; Marie-Claude Guertin Journal: JAMA Date: 2007-01-24 Impact factor: 56.272
Authors: Jordan W Smoller; Matthew Allison; Barbara B Cochrane; J David Curb; Roy H Perlis; Jennifer G Robinson; Milagros C Rosal; Nanette K Wenger; Sylvia Wassertheil-Smoller Journal: Arch Intern Med Date: 2009-12-14
Authors: William Whang; Laura D Kubzansky; Ichiro Kawachi; Kathryn M Rexrode; Candyce H Kroenke; Robert J Glynn; Hasan Garan; Christine M Albert Journal: J Am Coll Cardiol Date: 2009-03-17 Impact factor: 27.203
Authors: Elena Dragioti; Marco Solmi; Angela Favaro; Paolo Fusar-Poli; Paola Dazzan; Trevor Thompson; Brendon Stubbs; Joseph Firth; Michele Fornaro; Dimitrios Tsartsalis; Andre F Carvalho; Eduard Vieta; Philip McGuire; Allan H Young; Jae Il Shin; Christoph U Correll; Evangelos Evangelou Journal: JAMA Psychiatry Date: 2019-12-01 Impact factor: 21.596
Authors: Rasha Alqdwah-Fattouh; Sara Rodríguez-Martín; Francisco J de Abajo; Diana González-Bermejo; Miguel Gil; Alberto García-Lledó; Francisco Bolúmar Journal: Br J Clin Pharmacol Date: 2020-05-09 Impact factor: 4.335
Authors: Yu Ri Kim; Bo-Kyung Park; Young Hwa Kim; Insop Shim; In-Cheol Kang; Mi Young Lee Journal: Biomed Res Int Date: 2018-07-03 Impact factor: 3.411